Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: ##STR00001##
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.

Compounds of formula (I): wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b and R.sup.5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. ##STR00001##

Compounds of formula (I): wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b and R.sup.5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds are useful in treating inflammation and/or pain. Compositions comprising a compound of the invention are also disclosed, as are methods of using the compounds to treat inflammation and/or pain. ##STR00001##

The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.

The present application provides a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing these compounds, and methods of using these compounds for treating cancer, autoimmune diseases, and inflammatory diseases are also provided.

##STR00001##

The present application provides a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing these compounds, and methods of using these compounds for treating cancer, autoimmune diseases, and inflammatory diseases are also provided.

##STR00001##

The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The disclosure also relates to a method of treating a disease or disorder associated with ubiquitin-specific protease 28 (USP28) a method of treating cancer, and a method of inhibiting USP28, comprising administering to a subject in need thereof a compound of formula (I).

##STR00001##

Provided are a benzoindazolone compound, or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diasteromer, tautomer or prodrug thereof; and an intermediate thereof, wherein the compound is used as a substrate for NQO1 to facilitate a redox reaction of NQO1, and thus is expected to be developable as a medicine for preventing or treating inflammatory diseases.

Provided are a benzoindazolone compound, or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diasteromer, tautomer or prodrug thereof; and an intermediate thereof, wherein the compound is used as a substrate for NQO1 to facilitate a redox reaction of NQO1, and thus is expected to be developable as a medicine for preventing or treating inflammatory diseases.

The present disclosure relates to methods and intermediates useful for preparing a compound of formula I. ##STR00001##
or a co-crystal, solvate, salt or combination thereof.